从临床测量中推断阿尔茨海默病的病理特征 活着的成年人
Jingjing Yang1, Xizhu Liu2, Shahram Oveisgharan3
1Department of Human Genetics, Center for Computational and Quantitative Genetics, Emory University School of Medicine, Atlanta, GA, USA.
Journal of Alzheimer's disease : JAD
|March 1, 2024
概括
临床测量可以推断阿尔茨海默病的神经病理变化 (AD-NC),有助于识别患AD痴呆症 (ADD) 高风险的个体. 这些推断的AD-NC特征准确地预测了未来的ADD发展.
科学领域:
- 神经学 神经学
- 生物标志物 生物标志物
- 衰老研究研究 衰老研究
背景情况:
- 阿尔茨海默氏病的神经病理变化 (AD-NC) 对于识别患有阿尔茨海默氏病痴呆症 (ADD) 高风险的个体和确定ADD的亚型至关重要.
- 准确识别AD-NC对于及时干预和个性化治疗策略至关重要.
研究的目的:
- 开发和验证推算模型,以使用现有临床措施推断AD-NC.
- 评估推断AD-NC特征对事件ADD和死后确认的AD病理的预测能力.
主要方法:
- 惩罚性通用线性回归被用于训练四个AD-NC特征 (粉样β,,全球AD病理,病理性AD) 的归算模型.
- 模型使用Rush记忆和衰老项目的临床措施进行训练,并在宗教秩序研究 (ROS) 队列中得到验证.
- 推断的基线AD-NC特征被用来预测ROS参与者的事件ADD和死后病理AD.
主要成果:
- 在最后一次访问时推断的AD-NC特征与死后测量相关 (R2 = 0.1880.316) 和预测的病理性AD (AUC = 0.765).
- 推断的基线AD-NC特征显著预测了事件ADD,推断的病理AD显示出最强的预测能力 (AUC = 0.9190.896为35年的预测).
- 推断的基线AD-NC特征也在8年后对死后的病理性AD进行了歧视 (p < 1.4×10−10).
结论:
- 临床测量可以有效地用于推断老年成年人的AD-NC特征.
- 推断的AD-NC特征作为有希望的生物标志物用于估计AD-NC负担和预测未来的AD痴呆风险.
更多相关视频
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
14.0K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.9K
相关概念视频
Alzheimer's Disease: Overview
481
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481
Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188
